📊 TWST Key Takeaways
Is Twist Bioscience Corp (TWST) a Good Investment?
Twist Bioscience demonstrates solid revenue growth (+20.3% YoY) and a fortress balance sheet with $148.6M cash and minimal debt, providing multi-year financial runway. However, the company remains significantly unprofitable with -$30.5M net income and concerning cash burn of -$34.8M FCF, requiring substantial margin improvement or revenue acceleration to achieve sustainability.
Why Buy Twist Bioscience Corp Stock? TWST Key Strengths
- Strong revenue growth of +20.3% YoY demonstrating market traction in synthetic biology
- Excellent liquidity with $148.6M cash reserves and 3.78x current ratio
- Minimal debt with 0.00 debt/equity ratio providing maximum financial flexibility
TWST Stock Risks: Twist Bioscience Corp Investment Risks
- Significant negative cash burn of -$34.8M FCF limiting runway to approximately 4-5 years at current rate
- Deep unprofitability with -31.7% operating margin and -29.4% net margin
- Negative operating cash flow of -$24.8M indicates core business is not self-supporting yet
Key Metrics to Watch
- Quarterly revenue growth rate and acceleration trajectory toward profitability
- Operating cash flow trends and free cash flow burn rate deceleration
- Gross margin expansion and path to positive operating income
Twist Bioscience Corp (TWST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.78x current ratio provides a solid financial cushion.
TWST Profit Margin, ROE & Profitability Analysis
TWST vs Healthcare Sector: How Twist Bioscience Corp Compares
How Twist Bioscience Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Twist Bioscience Corp Stock Overvalued? TWST Valuation Analysis 2026
Based on fundamental analysis, Twist Bioscience Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Twist Bioscience Corp Balance Sheet: TWST Debt, Cash & Liquidity
TWST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Twist Bioscience Corp's revenue has grown significantly by 185% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.60 indicates the company is currently unprofitable.
TWST Revenue Growth, EPS Growth & YoY Performance
TWST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $88.7M | -$30.5M | $-0.50 |
| Q3 2025 | $81.5M | $20.4M | $0.33 |
| Q2 2025 | $75.3M | -$39.3M | $-0.66 |
| Q1 2025 | $71.5M | -$31.6M | $-0.53 |
| Q3 2024 | $63.7M | -$57.4M | $-1.01 |
| Q2 2024 | $60.2M | -$45.5M | $-0.79 |
| Q1 2024 | $54.2M | -$41.8M | $-0.74 |
| Q3 2023 | $56.1M | -$57.4M | $-1.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Twist Bioscience Corp Dividends, Buybacks & Capital Allocation
TWST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Twist Bioscience Corp (CIK: 0001581280)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TWST
What is the AI rating for TWST?
Twist Bioscience Corp (TWST) has an AI rating of HOLD with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TWST's key strengths?
Claude: Strong revenue growth of +20.3% YoY demonstrating market traction in synthetic biology. Excellent liquidity with $148.6M cash reserves and 3.78x current ratio.
What are the risks of investing in TWST?
Claude: Significant negative cash burn of -$34.8M FCF limiting runway to approximately 4-5 years at current rate. Deep unprofitability with -31.7% operating margin and -29.4% net margin.
What is TWST's revenue and growth?
Twist Bioscience Corp reported revenue of $103.7M.
Does TWST pay dividends?
Twist Bioscience Corp does not currently pay dividends.
Where can I find TWST SEC filings?
Official SEC filings for Twist Bioscience Corp (CIK: 0001581280) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TWST's EPS?
Twist Bioscience Corp has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TWST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Twist Bioscience Corp has a HOLD rating with 55% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TWST stock overvalued or undervalued?
Valuation metrics for TWST: ROE of -6.7% (sector avg: 15%), net margin of -29.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TWST stock in 2026?
Our dual AI analysis gives Twist Bioscience Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TWST's free cash flow?
Twist Bioscience Corp's operating cash flow is $-24.8M, with capital expenditures of $10.0M. FCF margin is -33.5%.
How does TWST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -29.4% (avg: 12%), ROE -6.7% (avg: 15%), current ratio 3.78 (avg: 2).